CD8A and neoplasm: A combination of anti-PD-1 and a synthetic STING agonist, MSA-2, led to significantly inhibited tumor growth compared to that with anti-PD-1 monotherapy in mouse tumor models by inducing CD8+ T-cell infiltration in tumors (67).